Active	Status	Sponsor type	Region	Phase	Filter
9 Active 0 Inactive 9 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

9 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Martinez, Luis
VERACITY, NCT04844749: Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent	Terminated	3	105	US	VERU-111, Sabizabulin, Enzalutamide, Abiraterone, XTANDI, Zytiga	Veru Inc.	Metastatic Castration-resistant Prostate Cancer, Androgen Resistant Prostatic Cancer	05/23	05/23
NCT04967664: Comparison of Qutenza (8% Capsaicin) With a Low-dose Capsaicin for Treatment of Nerve Pain After Surgery	Recruiting	3	408	Europe, US	Qutenza (capsaicin) 8% topical system, capsaicin 0.04% topical system	Averitas Pharma, Inc.	Post Surgical Neuropathic Pain	10/24	05/25
NCT05722522: Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy	Active, not recruiting	3	34	Europe, Canada, US, RoW	Secukinumab, AIN457, Placebo	Novartis Pharmaceuticals	Rotator Cuff Tendinopathy	10/24	12/24
NCT05281094: Efficacy and Safety of Two Doses of HIL-214 in Children	Active, not recruiting	2/3	3085	US, RoW	HIL-214, Placebo	HilleVax	Gastroenteritis	12/23	12/24
ARGON-2, NCT04378010: A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH	Terminated	2b	98	Europe, Canada, US, RoW	EDP-305 1.5 mg, EDP-305, EDP-305 2 mg, Placebo	Enanta Pharmaceuticals, Inc	Non-Alcoholic Steatohepatitis	10/21	11/21
NCT06282458: Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt	Active, not recruiting	2	150	US	Enobosarm, Semaglutide, Wegovy	Veru Inc.	Muscle Loss, Obesity	12/24	04/25
NCT05138822: Safety, Tolerability, Pharmacokinetic and Microbiological Investigation of GSK3882347 in Female Participants With Urinary Tract Infections	Recruiting	1	122	US	GSK3882347, Nitrofurantoin, Placebo	GlaxoSmithKline	Uncomplicated Urinary Tract Infections, Urinary Tract Infections	01/25	02/25
Alonso, Liuba
NCT06282458: Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt	Active, not recruiting	2	150	US	Enobosarm, Semaglutide, Wegovy	Veru Inc.	Muscle Loss, Obesity	12/24	04/25
Marinez, Diana
NCT06282458: Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt	Active, not recruiting	2	150	US	Enobosarm, Semaglutide, Wegovy	Veru Inc.	Muscle Loss, Obesity	12/24	04/25